Neurocrine Biosciences, Inc. (NBIX) Q4 2016 Earnings Results

Neurocrine Biosciences Misses on EPS, Stock Down 1.45%

The earnings report indicates that Neurocrine Biosciences is still facing challenges, as evidenced by the negative EPS. The stock reacted by dropping 1.45%, reflecting investor concerns about the company's current performance and lack of revenue data. The absence of guidance may also contribute to uncertainty among investors moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.51	N/A	+6.42%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing their commitment to long-term goals. They acknowledged the challenges faced in the quarter.

We are focused on our long-term strategy despite the current challenges.

Our pipeline remains a priority as we navigate through this period.

Neurocrine Biosciences Misses on EPS, Stock Down 1.45%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS, Stock Down 1.45%

Key numbers

Management commentary